Effectiveness and safety evaluation of terlipressin in the treatment of intestinal paralysis in end-stage liver disease

Table 5 Analysis of influencing factors for the prognosis on intestinal paralysis

	Univariate analysis			Multivariate analysis
Variable	OR	95% CI	P	OR	95% CI	P
Hepatic cirrhosis	0.47	0.06–3.89	0.482
Hepatic cancer	0.90	0.35–2.32	0.834
Diabetes	1.02	0.31–3.35	0.970
Hepatorenal syndrome	0.57	0.21–2.37	0.270
Gastrointestinal hemorrhage	1.02	0.31–3.35	0.970
Hepatic encephalopathy	0.63	0.20–1.93	0.416
Ascites			0.824
mild	0.52	0.13–2.07	0.355
moderate	0.79	0.26–2.42	0.678
large	0.91	0.27–3.11	0.886
WBC	0.92	0.83–1.02	0.097	0.9	0.81-1.00	0.060
N	0.99	0.97–1.02	0.597
K	0.69	0.36–1.34	0.270
Na	1.03	0.95–1.12	0.460
Fasting	1.13	0.34–3.73	0.847
Enema	3.33	0.86–12.90	0.081	7.23	1.58–33.09	0.011
Paraffin	1.82	0.67–4.96	0.243
Gastrointestinal decompression	0.30	0.11–0.79	0.015	0.23	0.08–0.68	0.008
Terlipressin	4.34	0.96–19.62	0.056	6.51	1.32–31.99	0.021

WBC, white blood cell; N, neutrophile granulocyte; K, Kalium; Na, natrium
Influencing factors related to intestinal paralysis remission were analyzed, including ascites, infection, gastrointestinal hemorrhage, obstruction location, clinical manifestations, electrolyte disturbances, and different treatment regimens. Then these factors were included in univariate logistic regression analysis. Furthermore, a multivariate logistic regression equation for factors with P < 0.1 was formed to analyze influencing factors on the prognosis of intestinal paralysis patients. The findings demonstrated that the presence or absence of enema (OR = 7.23, 95% CI 1.58–33.09, P = 0.011), gastrointestinal decompression (OR = 0.23, 95% CI 0.08–0.68, P = 0.008), and use of low-dose terlipressin (OR = 6.51, 95% CI 1.32–31.99, P = 0.021) had statistically significant effects on intestinal obstruction remission

ISSN: 1471-230X